guanethidine has been researched along with osteoprotegerin in 2 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 1 (50.00) | 24.3611 |
| 2020's | 1 (50.00) | 2.80 |
| Authors | Studies |
|---|---|
| Baroukh, B; Bataille, C; Brun, A; Chaussain, C; Cherruau, M; Haÿ, E; Marie, PJ; Mauprivez, C; Saffar, JL | 1 |
| Fan, D; Guan, Z; Huang, J; Jia, J; Leng, H; Li, Z; Song, C; Xu, Y; Yuan, W; Zhang, C; Zhang, W; Zhu, J | 1 |
2 other study(ies) available for guanethidine and osteoprotegerin
| Article | Year |
|---|---|
Different sympathetic pathways control the metabolism of distinct bone envelopes.
Topics: Animals; Cholinergic Fibers; Femur; Gene Expression Regulation; Guanethidine; Isoproterenol; Macrophage Colony-Stimulating Factor; Male; Mandible; Osteogenesis; Osteoprotegerin; Periosteum; Propranolol; RANK Ligand; Rats; Rats, Wistar; Receptors, Adrenergic, beta-2; Receptors, Vasoactive Intestinal Peptide; RNA, Messenger; Sympathectomy; Sympathetic Nervous System; Time Factors; Tyrosine 3-Monooxygenase; Vasoactive Intestinal Peptide | 2012 |
Bone mass loss in chronic heart failure is associated with sympathetic nerve activation.
Topics: Animals; Guanethidine; Heart Failure; Male; Osteoporosis; Osteoprotegerin; RANK Ligand; Rats; Rats, Sprague-Dawley; Saline Solution | 2023 |